Community Practice Connections™: 6th Annual School of Gastrointestinal Oncology®

Release Date: May 27, 2021
Expiration Date: May 27, 2022

Activity Overview

Multidisciplinary management and multimodality treatment of gastrointestinal cancers remain key concerns for community oncologists. Numerous advances in biomarkers, management, and development of novel targeted and immune-oncology therapies have contributed to significant advances in patient outcomes; however, the rapid evolution in the treatment landscape for these cancers makes it challenging to keep apace of breaking clinical data and updated treatment paradigms.

This online CME-certified educational activity provides an in-depth review of some of the key highlights from the 6th Annual School of Gastrointestinal Oncology^® (SOGO^®) held in March 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with gastrointestinal cancers, putting recent clinical trial data into clinical context. Renowned experts provide insights into recent clinical data with a focus on advances in colorectal cancer, cholangiocarcinoma, esophagogastric cancer, hepatocellular carcinoma, and pancreatic cancer. The program is designed for those who did not view the live webcast and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo Inc; Exelixis Inc; Genomic Health Inc; Incyte Corp; Merck & Co Inc; Pfizer Inc; and Taiho Oncology Inc.

Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, radiation oncologists, gastroenterologists, and hepatologists who are interested in the treatment of gastrointestinal (GI) cancers. Nurse practitioners, physician assistants, nurses, pathologists, pharmacists, and other health care professionals involved in the treatment and management of patients with GI cancers are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Use molecular markers to inform diagnosis and provide treatment guidance for patients with GI cancer
• Determine a comprehensive treatment plan for patients with early-stage GI cancer in the context of multidis¬ciplinary collaboration among radiation oncologists, surgical oncologists, and medical oncologists
• Optimize current treatment strategies based on guideline updates for patients with advanced GI cancer
• Incorporate novel treatment strategies into clinical practice to improve the outcomes of patients with GI cancer
• Assess management strategies to proactively mitigate treatment-related adverse events experienced by patients with GI cancer

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Daniel Catenacci, MD
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
The University of Chicago Medical Center
Chicago, IL

Disclosures: Consultant: Amgen, Genentech/Roche, and honoraria from Amgen, Archer Pharmaceuticals, Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Five Prime Therapeutics, Foundation Medicine, Genentech/Roche, Gritstone Oncology, Guardant Health, Merck, Natera Inc, Pieris Pharmaceuticals Inc, QED Therapeutics, Taiho Pharmaceutical, Tempus, Zymeworks Inc; Speakers’ Bureau: Eli Lilly, Genentech/Roche, Guardant Health, Merck, Tempus.

John L. Marshall, MD
Professor of Medicine and Oncology
Lombardi Comprehensive Cancer Center
Chief, Division of Hematology/Oncology
MedStar Georgetown University Hospital
Director, The Ruesch Center for the Cure of Gastrointestinal Cancers
Washington, DC

Disclosures: Grant/Research Support: Amgen, Bayer, Caris Life Sciences, Celgene, Indivumed GmbH, Merck, Taiho Oncology; Consultant: Amgen, Bayer, Caris Life Sciences, Celgene, Indivumed GmbH, Merck; Speakers’ Bureau: Amgen, Bayer, Caris Life Sciences, Celgene, Merck, Taiho Oncology.

Wells Messersmith, MD, FACP
Professor and Division Head, Medical Oncology
Associate Director for Translational Research
University of Colorado School of Medicine
Aurora, CO

Disclosures: Grant/Research Support: AstraZeneca, Celgene, Genentech/Roche, Immunomedics, Incyte, OncoMed Pharmaceuticals, Pfizer Inc, University of Colorado; Consultant: Data Monitoring Safety Committee: Five Prime Therapeutics.

Flavio G. Rocha, MD, FACS, FSSO
Associate Professor of Surgery
Hedinger Chair and Division Head, Surgical Oncology
Physician-in-Chief, Knight Cancer Institute
Oregon Health & Science University
Portland, OR

Disclosures: no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.